Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RARE logo RARE
Upturn stock ratingUpturn stock rating
RARE logo

Ultragenyx (RARE)

Upturn stock ratingUpturn stock rating
$29.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: RARE (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

20 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $86.05

1 Year Target Price $86.05

Analysts Price Target For last 52 week
$86.05 Target price
52w Low $25.81
Current$29.01
52w High $60.37

Analysis of Past Performance

Type Stock
Historic Profit 4.29%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.80B USD
Price to earnings Ratio -
1Y Target Price 86.05
Price to earnings Ratio -
1Y Target Price 86.05
Volume (30-day avg) 20
Beta 0.24
52 Weeks Range 25.81 - 60.37
Updated Date 08/15/2025
52 Weeks Range 25.81 - 60.37
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.48

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-05
When -
Estimate -1.3
Actual -1.17

Profitability

Profit Margin -87.34%
Operating Margin (TTM) -64.8%

Management Effectiveness

Return on Assets (TTM) -21.59%
Return on Equity (TTM) -180.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2354653363
Price to Sales(TTM) 4.58
Enterprise Value 2354653363
Price to Sales(TTM) 4.58
Enterprise Value to Revenue 3.86
Enterprise Value to EBITDA -6.46
Shares Outstanding 96371600
Shares Floating 92796064
Shares Outstanding 96371600
Shares Floating 92796064
Percent Insiders 3.14
Percent Institutions 100.27

ai summary icon Upturn AI SWOT

Ultragenyx

stock logo

Company Overview

overview logo History and Background

Ultragenyx Pharmaceutical Inc. was founded in 2003. It focuses on developing treatments for rare and ultra-rare genetic diseases. The company has grown from a research-focused startup to a commercial-stage biopharmaceutical company with multiple approved products.

business area logo Core Business Areas

  • Biologics: Development and commercialization of biologics for rare diseases, including enzyme replacement therapies and monoclonal antibodies.
  • Small Molecules: Development and commercialization of small molecule drugs for rare genetic disorders.
  • Gene Therapy: Development of gene therapies aimed at providing long-term or potentially curative treatments for genetic diseases.

leadership logo Leadership and Structure

Emil D. Kakkis, M.D., Ph.D., is the CEO. The organizational structure includes research and development, commercial operations, manufacturing, and administrative functions. The company has a board of directors overseeing strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • Crysvita (burosumab): Crysvita is a monoclonal antibody indicated for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Revenue in 2023 was significant, but specific market share data fluctuates and requires up-to-date sources. Competitors include Kyowa Kirin, the developer of Crysvita, with Ultragenyx commercializing in certain regions.
  • Dojolvi (triheptanoin): Dojolvi is a medium-chain triglyceride indicated for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Market share information varies; however, revenue is consistently growing and it is the only product approved for this indication. There are some alternative therapies and dietary management options for LC-FAOD.
  • Mepsevii (vestronidase alfa): Mepsevii is an enzyme replacement therapy used to treat Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. Ultragenyx has a dominant market share in this rare disease niche. Competitors are other companies developing therapies for rare diseases, though none specifically targeting MPS VII.
  • Evkeeza (evinacumab-dgnb): Evkeeza is a monoclonal antibody indicated as an adjunct to other lipid-lowering therapies for the treatment of adults and adolescents (u226512 years of age) with homozygous familial hypercholesterolemia (HoFH). It is in competition with products from Regeneron and Amgen.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, particularly the rare disease segment, is characterized by high R&D costs, complex regulatory pathways, and unmet medical needs. Increased regulatory incentives and scientific advancements are driving growth.

Positioning

Ultragenyx is a leader in developing therapies for rare and ultra-rare genetic diseases. Its competitive advantages include its focus on unmet medical needs, strong R&D capabilities, and expertise in navigating regulatory approvals for orphan drugs.

Total Addressable Market (TAM)

The overall rare disease market is estimated at hundreds of billions of dollars. Ultragenyx is positioned to capture a significant portion of this TAM through its diverse pipeline and approved therapies for specific indications.

Upturn SWOT Analysis

Strengths

  • Focus on rare diseases with high unmet needs
  • Strong R&D pipeline and drug development capabilities
  • Established commercial infrastructure for orphan drugs
  • Experienced management team with expertise in rare disease therapeutics
  • Proprietary technology platforms

Weaknesses

  • High R&D expenses and reliance on successful clinical trials
  • Dependence on a limited number of products for revenue generation
  • Challenges in manufacturing complex biologics
  • Potential competition from other companies developing therapies for the same rare diseases
  • Regulatory hurdles and pricing pressures

Opportunities

  • Expanding pipeline through internal R&D and strategic acquisitions
  • Geographic expansion into new markets
  • Leveraging gene therapy technologies to develop curative treatments
  • Collaborations and partnerships with other biopharmaceutical companies
  • Expanding indications for existing approved therapies

Threats

  • Clinical trial failures and regulatory setbacks
  • Competition from larger pharmaceutical companies with greater resources
  • Pricing pressures and reimbursement challenges for orphan drugs
  • Patent expirations and generic competition
  • Economic downturns impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • AMGN
  • GILD
  • VRTX

Competitive Landscape

Ultragenyx benefits from its focus on ultra-rare conditions, often facing less direct competition for individual indications. However, larger pharmaceutical companies with broader rare disease portfolios pose a competitive threat. Ultragenyx needs to continue to innovate in the space to capture more market share.

Major Acquisitions

GeneTx Biotherapeutics

  • Year: 2020
  • Acquisition Price (USD millions): 76
  • Strategic Rationale: Acquisition of GeneTx expanded Ultragenyx's pipeline with a potential treatment for Angelman syndrome.

Growth Trajectory and Initiatives

Historical Growth: Ultragenyx has experienced significant revenue growth since its first product approvals. The company's growth has been fueled by its focus on rare diseases and its ability to successfully commercialize its therapies.

Future Projections: Analysts project continued revenue growth for Ultragenyx, driven by the expansion of existing products and the potential approval of new therapies in its pipeline. Profitability is expected to improve over time as revenue scales and R&D expenses are managed.

Recent Initiatives: Recent initiatives include strategic acquisitions, pipeline expansion, and geographic expansion into new markets.

Summary

Ultragenyx is a focused biopharmaceutical company targeting rare and ultra-rare genetic diseases. While its revenue is growing, the company is not profitable, but it does have a strong R&D pipeline and established commercial infrastructure. High R&D expenses and competition from larger firms pose challenges, but the company is poised for growth through strategic acquisitions and pipeline expansion. It needs to watch competition and maintain its innovative edge.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Industry publications
  • Company Website

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and may vary based on source. Financial data is dynamic and should be verified with the latest company filings. This analysis uses past data to predict future results and is not indicative of actual future performance.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Ultragenyx

Exchange NASDAQ
Headquaters Novato, CA, United States
IPO Launch date 2014-01-31
Founder, President, CEO & Director Dr. Emil D. Kakkis M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 1294
Full time employees 1294

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.